Codexis (NASDAQ:CDXS) Announces Earnings Results, Misses Estimates By $0.09 EPS

Codexis (NASDAQ:CDXS) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.09), Zacks reports. The firm had revenue of $21.46 million for the quarter, compared to analyst estimates of $27.41 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. Codexis updated its FY 2025 guidance to EPS.

Codexis Stock Performance

Shares of CDXS stock opened at $3.93 on Friday. The company’s fifty day simple moving average is $4.60 and its 200-day simple moving average is $3.95. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. The firm has a market cap of $319.82 million, a PE ratio of -4.52 and a beta of 2.12. Codexis has a 12 month low of $2.56 and a 12 month high of $6.08.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Benchmark restated a “hold” rating on shares of Codexis in a report on Monday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 price target on shares of Codexis in a report on Friday, November 22nd.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.